Amgen (NASDAQ: AMGN) announced that CVS Health (NYSE:CVS) will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial formularies. "Ensuring access to Repatha for ...
Amgen Inc.’s AMGN new cholesterol-lowering medication, Repatha (evolocumab), a PCSK9 inhibitor, has found a place on CVS Health Corporation’s CVS formulary with CVS Health announcing that Repatha will ...
Amgen on Friday revealed its PCSK9 drug Repatha (evolocumab) reduced the risk of major adverse cardiovascular events but had no effect on cardiovascular death, mixed results which could spell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback